Antares Pharma Announces Submission of New Drug Application

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Antares Pharma Announces Submission of New Drug Application for Quickshot® Testosterone

EWING, N.J., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for QuickShot ® Testosterone (QST), a drug-device combination product for the delivery of testosterone enanthate using a subcutaneous auto injector.  QST is intended to treat adult men with low testosterone associated with a condition known as hypogonadism. 

“The submission of the QST New Drug Application represents yet another significant accomplishment for the Company in 2016.  It is the first product designed for subcutaneous delivery of testosterone through a fine gauge needle in patients diagnosed with hypogonadism,” said Robert F. Apple, President and Chief Executive Officer.  “We believe QST could be an excellent treatment option for men with hypogonadism.  In addition to virtually eliminating the risk of transference that exists with topical gel products and the uncomfortable deep intramuscular administration associated with current injectable therapies, the study data demonstrated that the QuickShot auto injector can provide patients with physiologically normal and steady levels of testosterone over the course of therapy. A potential added benefit to patients is a virtually painless treatment experience as demonstrated by the pain data collected in our phase 3 program. We will work closely with the FDA during the regulatory review process towards a potential approval with the goal of bringing this new treatment option to men diagnosed with hypogonadism.”

Two hundred and eighty-three men participated in the QST phase 3 program.  The phase 3 program consisted of a one year pivotal safety and efficacy study and a second 6-month safety study.  In the phase 3 program, patients received 75 mg of testosterone enanthate (TE) administered via the QuickShot ® device once-weekly for 6 weeks. At week 7, blinded dose adjustments were made if necessary based on week 6 pre-dose blood levels.  The patients continued to receive subcutaneous doses of 50 mg, 75 mg or 100 mg of testosterone weekly for up to 52 weeks.  The QuickShot ® testosterone auto injector has not been approved by the United States Food and Drug Administration.

About QuickShot ® Testosterone

The investigational subcutaneous testosterone enanthate auto injector is a proprietary, self-administered testosterone replacement option for men diagnosed with hypogonadism that is designed to be injected at home, on a weekly basis. Results from the previously reported Phase 3 pharmacokinetic study showed that testosterone delivered subcutaneously using the QuickShot ® testosterone auto injector provided rapid, steady, and reliable efficacy by restoring testosterone to pre-defined physiologic levels.

About QuickShot ® Auto Injector

The proprietary QuickShot ® auto injector is designed to allow rapid subcutaneous self-administration of highly viscous drugs such as testosterone and biologics using high spring pressure through a fine gauge needle.  Conventional auto injectors, or even a vial, needle and syringe could not inject these drugs efficiently or as fast and easy as the QuickShot ® device.  The QuickShot ® auto injector can also provide the patient with the ease and speed of self-administration, comfort and discretion.

About Hypogonadism

Hypogonadism, also known as testosterone deficiency or Low T, is a condition in which the body does not produce enough testosterone – the hormone that plays a key role in masculine growth and development during puberty, and maintenance of musculoskeletal, metabolic, and mental health in maturity.  Symptoms of male hypogonadism can be treated with testosterone replacement therapy.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company’s product, OTREXUP® (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company and Teva Pharmaceutical Industries, Ltd. (Teva) recently announced the third quarter 2016 U.S. commercial launch of VIBEX ® Sumatriptan Injection USP for the acute treatment of migraine and cluster headache.  Antares Pharma is also developing QuickShot ® Testosterone for testosterone replacement therapy. The Company's technology platforms include VIBEX ® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva that includes VIBEX ® epinephrine, exenatide multi-dose pen, and teriparatide multi-dose pen.  Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V.  The Company is also working with AMAG Pharmaceuticals on a subcutaneous method of administering Makena, a progesterone product indicated for use in lowering the risk of pre-term birth.  For more information, visit www.antarespharma.com .

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: U.S. Food and Drug Administration (“FDA”) acceptance of the Company’s NDA for QST and any FDA actions with respect thereto; FDA approval of the QST NDA and future market acceptance and revenue for QST; the outcome of the pending patent litigation between Teva Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly and Company regarding the Teriparatide multi-dose pen; FDA action with respect to Teva’s Abbreviated New Drug Application (“ANDA”) for the Teriparatide multi-dose pen and the timing and approval, if any, by the FDA of the same; Teva’s ability to adequately and timely respond to the Complete Response Letter received from the FDA for the VIBEX ® epinephrine pen ANDA and approval by the FDA of the same, the timing and therapeutic equivalence rating thereof, and any future purchase orders and revenue pre or post FDA approval; Teva’s ability to successfully commercialize VIBEX ® Sumatriptan Injection USP and the amount of revenue from the same; FDA action with respect to Teva’s ANDA filed for the Exenatide pen and future revenue from the same; continued growth of prescriptions and sales of OTREXUP ® ; the timing and results of the development project with AMAG Pharmaceuticals for an auto injector for Makena; the timing and results of research projects, clinical trials,  and product candidates in development; actions by the FDA or other regulatory agencies with the respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contact: Jack Howarth Vice President, Corporate Affairs 609-359-3016 jhowarth@antarespharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 70

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 96

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 228

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 70

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 166

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 85

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 103

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 110

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 83

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into abrdn Japan Equity Fund's Tender Offer Strategy

Updated Category News Views 303

Understanding the Tender Offer and Reorganization Process abrdn Japan Equity Fund, Inc. (NYSE: JEQ) is entering an exciting phase as it moves forward with additional details regarding its tender offer and the anticipated reorganization with abrdn Global Infrastructure Income Fund (NYSE: ASGI). As this process unfolds, it is essential for investors to grasp the key details...

Continue Reading
TriNet Welcomes Sidney Majalya as New Chief Legal Officer

Updated Category News Views 158

TriNet Welcomes New Chief Legal Officer TriNet, a prominent provider of comprehensive human resources solutions tailored for small and medium-sized businesses, has recently undergone notable leadership changes. The company is excited to announce the appointment of Sidney Majalya as its new Chief Legal Officer and Secretary, marking an important milestone in its evolution....

Continue Reading
Exploring the Future Growth of the SDx Market by 2034

Updated Category News Views 94

Understanding the Growth of the Software-Defined Anything Market The global Software-Defined Anything (SDx) market is experiencing a remarkable transformation. Recently, it was reported that the market is set to grow from USD 44.46 billion in 2024 to an estimated USD 383.65 billion by 2034, achieving a compound annual growth rate (CAGR) of 24.0%. This expansion signals a...

Continue Reading
Safe Harbor Financial Strengthens Position After Successful Capital Raise

Updated Category News Views 245

Safe Harbor Financial's Significant Achievements Recently, Safe Harbor Financial, known as SHF Holdings, Inc. (NASDAQ: SHFS), celebrated a considerable milestone. They regained compliance with Nasdaq's listing requirements, proving their resiliency in the dynamic financial services sector aimed at the cannabis industry. This success was paired with a noteworthy capital...

Continue Reading
UNITE's Dignity Index: Insights from the Vance-Walz Debate

Updated Category News Views 125

UNITE Unveils Dignity Index Results Post-Debate UNITE, a non-profit organization aimed at reducing political divisions, recently showcased its Dignity Index scores following the Vice-Presidential debate between Senator J.D. Vance and Governor Tim Walz. This initiative was co-founded by Tim Shriver, who emphasizes the importance of dignity in political discourse. The...

Continue Reading